What Will Decide Vertex Stock Over The Next Six Months? Trefis Team Wed, November 11, 2026 at 10:38 AM EST 4 min read VRTX -1.44% ^GSPC +1.11% REGN -0.20% BMRN -0.12% ALNY +3.09% Explore stocks on Coinbase Trading disclosure Trading disclosure The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
For questions about this article or underlying research, email help@trefis.com.
Vertex Pharmaceuticals (VRTX) stock returned 33.8% over the past twelve months, against 13.1% for the S&P 500. On its November 2, 2026 call, management said Vertex, which sold only cystic fibrosis medicines in 2019, will soon sell medicines in five disease areas, and several of those medicines face tests over the next six months. Below are the events most likely to move Vertex stock over that time and just after it, starting with an FDA decision due on November 30, 2026.
Interim AMPLITUDE results for inaxaplin, the basis for a U.S. accelerated approval filing
Proof-of-concept data for povetacicept in generalized myasthenia gravis, from a Phase 2 study that has finished enrolling
JOURNAVX patient support program stays on, keeping the gap between list and net price wide
The FDA's target date for a ruling on accelerated approval of povetacicept for adults with IgA nephropathy, a kidney disease, is November 30, 2026. The application is under priority review, and management said on the November 2 call that Vertex is ready for the date.
Approval would add kidney disease to the areas where Vertex sells medicines. The company still earns most of its revenue from cystic fibrosis, and TRIKAFTA/KAFTRIO made up 85.9% of revenue in fiscal 2025. When asked on the call about an anonymous citizen petition on the IgG monitoring and dose-hold rules in the drug's label, management said about 200 citizen petitions are filed every year, and about 20% are anonymous. The wording of the FDA's label is the detail to watch on November 30.
Vertex plans to share interim results from AMPLITUDE, its pivotal trial of inaxaplin in a kidney disease called AMKD, in early 2027. The company will release the data once the interim group has been treated for 48 weeks. Vertex would use those results to seek U.S. accelerated approval.
Management said Vertex and the FDA agreed that GFR, a standard measure of kidney function, is what counts for that approval, and that Vertex is looking for a statistically significant difference against placebo. The change in GFR against placebo is the result to watch in early 2027.
JOURNAVX's Patient Support Program
On the November 2 call, management said Vertex will keep its patient support program for JOURNAVX, its pain medicine, running until the middle of 2027. The program helps patients whose insurance plans do not yet cover the drug. Management called it a big driver of the gap between JOURNAVX's list price and what Vertex collects.
That gap shows in the fiscal Q3 2026 figures. JOURNAVX prescriptions rose more than 40% from fiscal Q2 2026, while its revenue rose 18%. Management said a one-time reset after broad Medicare Part D access began in July 2026 also held down the quarter's revenue. Management expects the gap to settle at 50% to 60% of list price once the program ends, and it expects more than $0.5 billion of 2026 revenue from JOURNAVX and CASGEVY together. JOURNAVX revenue in the fiscal Q4 2026 report, expected in February 2027, is the number to watch.
Can You Hold Vertex Stock Through These Dates?
Over the past year, Vertex stock's deepest fall was 15.2%, from March 10 to April 29, 2026, across 35 trading sessions. Results days have moved the shares too. The stock fell 5.0% around the November 2, 2026 call and rose 6.6% around the February 12, 2026 call. The May and August 2026 calls each moved it by less than 0.5%.
If you could carry another fall that deep in your Vertex holding without selling, the holding is sized for these dates. If it would push you to sell, a smaller holding is the one that can sit through them.
Does This Mean You Should Act On VRTX?
Betting on a single stock is always risky, whichever way you lean. The Trefis High Quality (HQ) Portfolio holds 30 quality companies in equal weight and has returned 105% since its September 2020 launch.
Spot an error or want more like this? Tell us in 10 seconds.
